Related Experiment Video
Updated: Nov 4, 2025

Setup of Consumer Wearable Devices for Exposure and Health Monitoring in Population Studies
Published on: February 3, 2023
The impact of COVID-19 on familial Mediterranean fever: a nationwide study
Zafer Günendi1, Fatma Gül Yurdakul2, Hatice Bodur3
1Division of Rheumatology, Department of Physical Medicine and Rehabilitation, Faculty of Medicine, Gazi University, Ankara, Turkey.
Insights
Familial Mediterranean fever (FMF) patients generally experienced mild coronavirus disease 2019 (COVID-19). FMF characteristics did not appear to increase the risk of severe COVID-19 outcomes like hospitalization.
Area of Science:
- Rheumatology
- Infectious Diseases
- Genetics
Background:
- Familial Mediterranean fever (FMF) is a genetic autoinflammatory disorder.
- The impact of FMF on coronavirus disease 2019 (COVID-19) susceptibility and severity is not well understood.
Purpose of the Study:
- To evaluate the impact of COVID-19 in patients with FMF.
- To assess the relationship between FMF characteristics and severe COVID-19 outcomes.
Main Methods:
- A national network of 21 centers collected data on 822 FMF patients.
- Demographics, FMF clinical/genetic data, and COVID-19 outcomes were analyzed.
Main Results:
- Seven percent of FMF patients (59/822) were diagnosed with COVID-19, mostly with mild to moderate disease.
- Hospitalized COVID-19 patients with FMF were older; other FMF characteristics showed no association with poor outcomes.
- Complications included thromboembolism and acute respiratory distress syndrome in two patients.
Conclusions:
- FMF itself may not be a significant risk factor for severe COVID-19 outcomes.
- Colchicine compliance and resistance were noted in a subset of FMF patients with COVID-19.
Abstract:
The study aimed to evaluate the impact of the coronavirus disease 2019 (COVID-19) in patients with familial Mediterranean fever (FMF) and to assess the relationships between FMF characteristics and severe COVID-19 outcomes such as hospitalization. The study was planned within a national network of 21 different centers. Demographics, FMF-related clinical and genetic characteristics, and COVID-19 outcomes were obtained. A total of 822 patients with FMF (mean age of 36 years) were included in the study. Fifty-nine of them (7%) had a COVID-19 diagnosis confirmed by real-time PCR test or chest CT findings. Most FMF patients with COVID-19 (58) had mild and moderate disease activity. All patients were on colchicine treatment. However, 8 of them (13.6%) were not compliant with colchicine use and 9 of them (15.3%) were colchicine resistant. Twelve FMF patients with COVID-19 were hospitalized. There were 4 patients requiring oxygen support. COVID-19 related complications were observed in 2 patients (1 thromboembolism, 1 acute respiratory distress syndrome). Hospitalized COVID-19 patients with FMF were older than non-hospitalized patients (median ages: 51 and 31 years, respectively; p: 0.002). Other FMF-related characteristics were similar between the groups. FMF-related characteristics were not found to be associated with poor outcomes in COVID-19. Thus, FMF may not be a risk factor for poor COVID-19 outcomes.
Related Concept Videos
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Myocarditis II: Clinical Features and Diagnostic Tests
Factors Affecting Illness
For instance, risk factors are connected to illness,...
Bias in Epidemiological Studies
Myocarditis III: Medical Management
Myocarditis I: Introduction

